Edwards Lifesciences price target raised to $96 from $86 at Canaccord Canaccord raised its price target on Edwards Lifesciences (EW) to $96 based on the worldwide patent litigation settlement with Medtronic (MDT). The firm believes the agreement removes an expensive distraction for the business and retains the goodwill of physicians. Shares are Buy rated.
Edwards Lifesciences price target raised to $120 from $95 at Piper Jaffray Piper Jaffray raised its price target for Edwards Lifesciences shares to $120 saying recent Transcatheter Aortic Valve Replacement market momentum is likely to continue. The firm keeps an Overweight rating on the stock.